



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Rory A.J. Curits and M.
Alexandra Glucksmann

Serial No.: 09/174,937

Filed: October 19, 1998

For: *ISOLATED PROTEINS AND NUCLEIC ACID
MOLECULES HAVING HOMOLGY TO THE NIP2
PROTEIN AND USES THEREOF*

Attorney Docket No.: MNI-061

Group Art Unit: 1653

Examiner: Bugaisky, G.

Assistant Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

5/9/00
Date of Signature and of Mail Deposit

By:

Maria C. Laccotripe
Maria C. Laccotripe, Ph.D.
Agent for Applicant
Limited Recognition Under 37 CFR §10.9(b)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Applicants and their agent have become aware of the following publication, cited in an International Search Report mailed February 10, 2000 during the prosecution of PCT/US99/24335 which corresponds to the above referenced application. In accordance with 37 CFR §1.97(c)(1), Applicants hereby submit this publication for the Examiner's consideration. This publication is cited on the enclosed PTO Form 1449, and a copies of the Report and the publication cited thereon are enclosed as well.

This statement is not to be interpreted as a representation that the cited publication is material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publication.

Pursuant to 37 C.F.R. § 1.97 (e)(1) the undersigned hereby certifies that the item contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


Maria C. Laccotripe, Ph.D.
Agent for Applicant
Limited Recognition Under 37 CFR §10.9(b)

28 State Street
Boston, MA 02109
(617) 227-7400

Date: 5/9/00

AEM/MCL/mlh
Enclosures